Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Late Breaking Abstract Submission     Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Discussion 3

Poster Discussion 3 
  Endocrine Resistance
PD3-1 Serial next generation sequencing (NGS) of poor prognosis luminal tumors across treatment history reveals both de novo and acquired alterations potentially associated with endocrine resistance
Giltnane JM, Balko JM, Wang K, Kuba MG, Mehndi M, Stricker TP, Sanders ME, Yelensky R, Stephens PJ, Miller V, Arteaga CL. Vanderbilt-Ingram Cancer Center, Nashville, TN; Foundation Medicine, Cambridge, MA.
PD3-2 Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment
Turnbull AK, Arthur L, Webber V, Larionov AA, Renshaw L, Kay C, Dunbier A, Dowsett M, Sims AH, Dixon JM. Breakthrough Research Unit, Western General Hospital, Edinburgh, United Kingdom; Breakthrough Research Unit, The Royal Marsden, London, United Kingdom.
PD3-3 Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer
Iggo RD, Wood HM, Rabbitts P, Quenel-Tueux N, Mauriac L, MacGrogan G, Bonnefoi H, HORGEN Investigators. INSERM U916, Univ. Bordeaux, Institut Bergoniť, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom.
PD3-4 A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
Goetz MP, Suman VA, Reid JR, Northfelt DW, Mahr MA, Dockter T, Haluska PJ, Kuffel M, Burhow S, Safgren S, McGovern R, Collins J, Streicher H, Hawse JR, Erlichman C, Ingle JN, Ames MM. Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; NCI, Bethesda, MD.
PD3-5 Survival benefit conferred by the androgen receptor is lost in aromatase inhibitor treated breast cancer
Ali A, Bane F, Hao Y, McCartan D, O'Gaora P, Hill ADK, Young LS, McIlroy M. Endocrine Oncology Research Group, RCSI, Dublin, Ireland; School of Medicine and Medical Sciences, UCD, Dublin, Ireland; Beaumont Hospital, Dublin, Ireland. Azlena Ali is a recipient of an SABCS Clinical Scholars scholarship
PD3-6 A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer
Traina TA, Yardley DA, Patel M, Schwartzberg L, Elias A, Gucalp A, Peterson AC, Hannah A, Gibbons J, Khondker Z, Hudis CA, LoRusso P. Memorial Sloan-Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists and Research Institute, Sarasota, FL; The West Clinic, Memphis, TN; University of Colorado Anschutz Medical Campus, Aurora, CO; Medivation Inc., San Francisco, CA; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI.
PD3-7 Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study)
Miura D, Hasegawa Y, Horiguchi J, Ishikawa T, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Kaise H, Akazawa K, Kohno N. Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan; Hirosaki Municipal Hospital, Aomori, Japan; Breast and Endocrine Surgery, Gunma University Hospital, Gumma, Japan; Breast and Thyroid Surgery, Yokohama City University Medical Center, Kanagawa, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Breast and Endocrine Surgery, Osaka University Hospital, Osaka, Japan; Kitasato University School of Medicine, Kanagawa, Japan; Konan Hospital, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan; Yodogawa Christian Hospital, Osaka, Japan; Shinko Hospital, Hyogo, Japan; Tokyo Medical University Hospital, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan.
PD3-8 Whole exome sequencing reveals early mutational change on endocrine and targeted therapy in estrogen receptor (ER)-positive breast cancer
Massarweh S, Romond E, Wang C, Zeng Z, Liu J, Stewart R, Napier D, Kadamyan-Melkumyan V, Farman M, Black EP. University of Kentucky and Markey Cancer Center.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy